Trustpilot4.1/5 · 25 reviews
Skip to main content

Nonsensia

A peak at 0.12 percent of total area is either a one-line entry in a batch record or three months of work, and the number alone does not decide which. What decides it is whether anyone knows what the peak is. That is the difference between a reporting threshold and an identification threshold, and it is why impurity profiling is a structural exercise before it is a quantitative one.

ICH Q3A(R2) sets those limits for new drug substances produced by chemical synthesis. It explicitly excludes biological and biotechnological products, peptides, oligonucleotides, radiopharmaceuticals, fermentation products and semi-synthetic products derived from them, herbal products, and crude products of animal or plant origin. It is also not intended to apply to substances in the clinical research stage. The exclusions matter, because the figures below are routinely quoted far outside the scope in which they were written.

The difference between a reporting threshold and an identification threshold

Three thresholds sit in Attachment 1 of the guideline. All three are keyed to the maximum daily dose of the drug substance, not to the substance itself, so the same chromatographic peak carries a different obligation in a 200 milligram product than in a 3 gram one.

Maximum daily dose Reporting threshold Identification threshold Qualification threshold
Not more than 2 g/day 0.05% 0.10% or 1.0 mg per day intake, whichever is lower 0.15% or 1.0 mg per day intake, whichever is lower
Above 2 g/day 0.03% 0.05% 0.05%

The guideline attaches two footnotes to that table. A higher reporting threshold has to be scientifically justified. A lower threshold can be appropriate where an impurity is unusually toxic. Neither footnote is optional decoration; both are the hinge on which most real negotiations with an assessor turn.

One sentence in Section 4 constrains the whole scheme: the quantitation limit of the analytical procedure should be not more than the reporting threshold. A method that cannot quantify at 0.05 percent cannot support a specification written around 0.05 percent, whatever the chromatogram looks like. The guideline also fixes the arithmetic of reporting. Below 1.0 percent, results go to two decimal places, as in 0.06 percent or 0.13 percent. At and above 1.0 percent, one decimal place, as in 1.3 percent.

Why an unidentified peak outranks a larger identified one

The glossary separates two axes that are constantly conflated. An impurity is identified or unidentified depending on whether a structural characterisation has been achieved. It is specified or unspecified depending on whether the specification lists it individually with its own acceptance criterion.

Those axes are independent, and the combination the guideline explicitly permits is the informative one: a specified impurity can be unidentified. Q3A even prescribes how to name such a thing. It is referred to by a qualitative analytical descriptive label, for example “unidentified A” or “unidentified with relative retention of 0.9”. That phrasing is a small admission with large consequences. It concedes that a compound can be controlled by a number while remaining, chemically, a retention time.

Everything not individually listed falls under a general acceptance criterion of not more than the identification threshold for any unspecified impurity, plus a separate criterion for total impurities. So the identification threshold does double duty. It is the level above which a structure must be pursued, and it is the ceiling under which anonymous material is tolerated in bulk.

This is the concrete sense in which identity outranks quantity. An identified impurity at 0.4 percent that is also a known human metabolite may already be qualified. An unidentified peak at 0.11 percent in a 1 gram product is an open toxicological question, because nothing about a retention time predicts what a compound does.

What qualification of an impurity actually asks for

Qualification is defined as the process of acquiring and evaluating data that establishes the biological safety of an individual impurity, or of a given impurity profile, at the levels specified. Two shortcuts are written into the guideline itself. Any level of an impurity present in material that has already been adequately tested in safety or clinical studies counts as qualified. Impurities that are also significant metabolites in animal or human studies are generally considered qualified.

Where neither shortcut applies, the guideline calls for study data without saying much about the study. Mitra and colleagues documented that gap in 2021 for the IQ consortium: Q3A(R2) and Q3B(R2) point to one nonclinical species for 14 to 90 days but specify neither species selection, nor design, nor which duration supports which clinical duration. Their survey of member companies found the predictable result, a spread of ad hoc designs, and produced harmonised designs projected to cut animal numbers by up to 90 percent.

Harvey and colleagues had earlier attacked the same gap from the safety side. Their 2017 analysis of in vivo toxicology databases supported the Q3A premise that a lifetime intake of 1 mg per day of a non-mutagenic organic impurity does not represent a safety concern, and proposed that figure as a universal qualification threshold across clinical development, with a Haber’s law adjustment for exposures shorter than six months.

How unknown impurities are structurally characterised

Identification work is a funnel, and the chromatographic peak is only the entrance. Accurate mass from high-resolution mass spectrometry narrows the elemental composition. Multistage fragmentation locates where the molecule differs from the parent. Nuclear magnetic resonance settles regiochemistry when enough material can be isolated. Hydrogen-deuterium exchange counts labile hydrogens, which separates a hydroxylated analogue from an isomer of the same nominal mass.

Thakkar and colleagues coupled these into one experiment in 2023, running liquid chromatography into a diode array detector, then splitting the flow to a charged aerosol detector with an inverse gradient and to an Orbitrap analyser, with on-demand D2O infusion for partial exchange. Across four model compounds and nineteen chromatographic peaks, the arrangement returned exact mass, fragmentation, labile hydrogen count and a weight-by-weight figure in a single run.

Why area percent is not the same as weight percent

The charged aerosol arm of that experiment addresses a problem Q3A states plainly. Impurity levels are usually measured by comparing an analytical response against a reference standard or against the response of the drug substance itself. Where the response factors of the drug substance and the impurity are not close, the guideline permits the practice only if a correction factor is applied, or if the impurities are in fact being overestimated.

Ultraviolet response scales with the chromophore, not with mass. An impurity that has lost a conjugated ring can under-respond by a large factor, so its area percent figure understates it. The regulatory requirement is a weight-by-weight number, and the bridge between the two is a relative response factor, which requires an isolated, characterised standard of the impurity. Early in development that standard usually does not exist, which is exactly when the profile is least well understood. The guideline’s own instruction is that reference standards used in impurity procedures be evaluated and characterised according to their intended use; material sold as an analytical reference standard earns that description through its characterisation data, not through a purity figure on a label.

The case against counting every peak

The identity-first position has serious critics, and they are worth reading. Snodin and McCrossen argued in 2012 that the derivation of impurity limits contains real deficiencies and generates toxicological anomalies, and that tightly controlling numerous impurities, particularly minor structural variants of the active substance, is likely to produce minimal improvement in drug safety. Their closing point has aged well: detection limits keep falling, and the temptation to translate that sensitivity straight into regulatory limits without a safety evaluation should be resisted.

That is not an argument against knowing what a peak is. It is an argument that knowing what the peak is should determine how hard it is controlled, rather than the instrument determining it. A structure supports a read-across, a metabolite claim, a computational assessment. A retention time supports none of those, which is why the cheapest thing an impurity profile can contain is a number without a name.

Frequently asked questions

What is the identification threshold for an impurity in a new drug substance?

Under ICH Q3A(R2), for a maximum daily dose of not more than 2 grams per day the identification threshold is 0.10 percent, or 1.0 mg per day of total intake, whichever is lower. Above 2 grams per day it falls to 0.05 percent. A lower threshold can apply where the impurity is unusually toxic.

What is the difference between a specified and an unspecified impurity?

A specified impurity is listed individually in the specification with its own acceptance criterion. An unspecified impurity is covered only by a general criterion, normally set at not more than the identification threshold. A specified impurity may be either identified or unidentified, so specification status describes control, not chemical knowledge.

Does an impurity below the reporting threshold have to be measured?

It does not have to be reported in the application, but the analytical procedure must be capable of seeing it. ICH Q3A(R2) states that the quantitation limit of the procedure should be not more than the reporting threshold. Potential impurities expected to be unusually potent require methods sensitive well below that level.

Why is an unidentified impurity treated as a bigger problem than a known one?

Because structure is what safety arguments are built from. A known impurity can be matched to a metabolite, to published toxicology, or to a computational prediction. An unidentified peak defined only by retention time supports none of those arguments, so it has to be controlled conservatively however small the number is.

Can area percent be reported as weight percent on a certificate of analysis?

Only when the response factors are close or a correction factor has been applied. Ultraviolet response depends on the chromophore, so an impurity with weaker absorbance is understated by area normalisation. Converting to a weight-by-weight figure needs a relative response factor, obtained from an isolated impurity standard or from a mass-sensitive detector.

What does it mean to qualify an impurity?

Qualification is the process of acquiring and evaluating data that establish the biological safety of an impurity, or of a whole impurity profile, at the specified level. Material already covered by adequate safety or clinical testing counts as qualified, and impurities that are significant metabolites in animal or human studies are generally considered qualified.

Do ICH Q3A thresholds apply to peptides and biological products?

No. The guideline states that biological and biotechnological products, peptides, oligonucleotides, radiopharmaceuticals, fermentation products and semi-synthetic derivatives of them, herbal products and crude products of animal or plant origin are outside its scope. It is also not intended for substances in the clinical research stage, where phase-appropriate approaches apply instead.

References

  1. ICH Q3A(R2), Impurities in New Drug Substances — thresholds, glossary and qualification
  2. Thakkar et al., Journal of Chromatography A, 2023 — LC-DAD-CAD-HRMSn with online hydrogen/deuterium exchange
  3. Mitra et al., Regulatory Toxicology and Pharmacology, 2021 — harmonised non-mutagenic impurity qualification study designs
  4. Harvey et al., Regulatory Toxicology and Pharmacology, 2017 — safe limits for organic impurities in early development
  5. Snodin and McCrossen, Regulatory Toxicology and Pharmacology, 2012 — critical assessment of impurity guidances
  6. Ramamoorthy, Pharmaceutical Research, 2026 — impurity characterisation across drug development stages

Research use only. Nonsensia supplies analytical reference standards for laboratory and research applications. This article is published for scientific and educational purposes. It is not medical advice, it does not describe any use in humans, and nothing in it should be read as a recommendation to administer any substance to a person or animal.

Filed under: Purity & Quality Control

This article is part of our guide to What Purity Actually Means: Impurities, Certificates and Specifications.